SPSIPB vs. SAPB in Breast Surgery
Serratus Posterior Superior Intercostal Plane Block Versus Serratus Anterior Plane Block for Breast Surgery: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kozlu
-
Zonguldak, Kozlu, Turkey, 67600
- Zonguldak Bülent Ecevit University Medicine Faculty
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who have received informed consent form Patients who will undergo Breast Cancer Surgery aged between 18-65
Exclusion Criteria:
- <18 years and >65 years
- ASA ≥ IV
- History of allergy to local anesthetics
- Clinical diagnosis of coagulation disorders
- Infection near the entry site
- Chronic analgesic use Patients who will undergo bilateral Breast Cancer Surgery
- Body mass index >35
- Clinical diagnosis of Dementia or confusion
- Lack of cooperation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Group Control
|
|
|
Active Comparator: Group SPSIPB
|
administer 30 mL %0.25 bupivacain between third costa and serratus posterior superior muscle
|
|
Active Comparator: Group SAPB
|
administer 30 mL %0.25 bupivacain between 5th costa and serratus anterior muscle in midaxiller line
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative opioid consumption
Time Frame: up to 24 hour after surgery
|
total opioid consumption during postoperative 24 hours
|
up to 24 hour after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative pain scores
Time Frame: postoperative 2nd 6th, 12th 24th hour
|
Pain scores evaluate with Numeric rating scale.
0= no pain, 10= unbearable pain
|
postoperative 2nd 6th, 12th 24th hour
|
|
quality of recovery
Time Frame: postoperative 24 hour
|
Recovery quality will be measured with Quality of recovery-15 questionnaire
|
postoperative 24 hour
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025/01-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.